ArticleFEBS open bio2026
Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Adipogenesis involves preadipocyte proliferation and differentiation into mature adipocytes, with dysregulation of this process being associated with changes in metabolic health. Here, we aimed to evaluate the effect of IGFBP4 knockdown (KD) on human preadipocytes and define if this altered IGF1 signaling. We assessed proliferation, adipogenic differentiation, gene expression, and the activation of the IGF1 receptor (IGF1R)/AKT pathway across different human adipocyte models. Our findings show IGFBP4 KD impaired proliferation and caused a reduction in IGF1R and phosphorylated AKT (Ser473) proteins, although no difference in adipogenic differentiation was observed. Furthermore, while adding recombinant human IGFBP4 did not reverse this effect, protein synthesis inhibition abolished IGFBP4 KD-mediated IGF1R downregulation when cotreated with a proteasomal inhibitor but not with a lysosomal inhibitor. We conclude that IGFBP4 knockdown is associated with IGF1R downregulation, impaired AKT phosphorylation, and suppressed proliferation, suggesting IGFBP4 is a critical regulator of IGF1R homeostasis in human preadipocytes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.